• Home
  • Project
  • Partners
    • Advisory board
    • Investigators
    • Institutes
      • LUMC
      • Inserm
      • UCL
      • Great Ormond Street
      • Ospedale San Raffaele
      • Hannover Medical School
      • University of Ulm
      • Wroclaw University
      • Newcastle University
      • IPOPI
      • Batavia Biosciences
      • Vall d’Hebron Hospital
      • Bambino Gesù
      • SCETIDE
      • Sheba Medical Center
      • LMU
      • GeneWerk
    • Partner area
  • Impact
  • Resources
    • Leaflet
    • Videos
  • Contact
  • News

Slide RECOMB Clinical trial for RAG1-SCID
home_science_icon5

Develop

Develop an autologous haematopoietic stem cell‒based gene therapy within a multinational, multicentre clinical trial for treating RAG1-SCID.
home_science_icon4

Treat

Treat the patients with the developed RAG1-SCID gene therapy eliminating complications and increasing survival.
home_science_icon1

Impact

Make gene therapy a realistic option for > 70% of all SCID patients in Europe with reduced healthcare costs.
parallax background

News


Read more
March 13, 2023

Ethical approval at Vallhebron

Do you like it?23
0 Read more
March 1, 2023

Second patient recruited to our RAG1 trial

Do you like it?23
0 Read more

About us

The RECOMB consortium brings together a large number of clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID.

Our mission

The ultimate aim of RECOMB is to create a treatment for the most common type of SCID, RAG1-SCID by performing phase 1 and phase 2 clinical trials using autologous haematopoietic stem cell‒based gene therapy.

Useful links

  • Learn more about Primary immunodeficiencies
  • Learn more about SCID
  • Learn more about Gene Therapy

This project has received funding from the  European Union’s Horizon 2020 research and 
innovation programme under grant agreement n° 755170’

© 2023 RECOMB. All Rights Reserved. Muffin group